| Old Articles: <Older 8531-8540 Newer> |
|---|
 |
Chemistry World
February 14, 2013
Patrick Walter |
Drugs to blame for anti-social fish Swedish scientists say that low levels of psychotherapeutic drugs can change the way fish behave and could be altering the balance of entire aquatic food webs.   |
Pharmaceutical Executive
February 1, 2013
Julian Upton |
Turkey: A Promise Restored? After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. |
Pharmaceutical Executive
February 1, 2013
Stan Bernard |
Why Product Lifecycle Management Fails Pharma: Time for a Rethink? Pharma professionals adopting the "Drug Life Optimization" approach can wrest more value through strategies that build and promote a drug's brand franchise through its entire lifespan, not simply the product lifecycle. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
February 1, 2013 |
Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally. |
Pharmaceutical Executive
February 1, 2013
Julin et al. |
Fortuity and the First Amendment Caronia decision shows the staying power of Sorrell v. IMS Health. Don't bank just yet on putting your marketing muscle behind the safe and effective off-label uses of your FDA-approved drugs. |
Pharmaceutical Executive
February 1, 2013
Jill Wechsler |
Breakthrough Year for New Drugs More new medicines gained market approval, but marketers face resistance from payers looking to cut healthcare spending. |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Chemistry World
February 8, 2013
Rachel Cooper |
Printing crystalline drugs A group of UK chemists has used a desktop inkjet printer to prepare a metastable form of the anti-epileptic drug carbamazepine. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
| <Older 8531-8540 Newer> Return to current articles. |
